Press coverage about Sophiris Bio (NASDAQ:SPHS) has trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sophiris Bio earned a news sentiment score of 0.23 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.2550977381422 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of Sophiris Bio (NASDAQ:SPHS) traded up $0.01 during trading on Friday, hitting $2.29. 121,281 shares of the company were exchanged, compared to its average volume of 246,458. The firm has a market cap of $68.95, a PE ratio of -12.72 and a beta of 1.41. The company has a quick ratio of 13.37, a current ratio of 13.37 and a debt-to-equity ratio of 0.60. Sophiris Bio has a 1-year low of $1.80 and a 1-year high of $3.24.

A number of equities analysts have recently commented on SPHS shares. Maxim Group set a $6.00 price objective on shares of Sophiris Bio and gave the stock a “buy” rating in a report on Monday, October 2nd. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Sophiris Bio in a report on Friday, November 10th. Finally, ValuEngine upgraded shares of Sophiris Bio from a “strong sell” rating to a “sell” rating in a research report on Friday, December 15th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $6.25.

TRADEMARK VIOLATION NOTICE: This news story was first posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://www.watchlistnews.com/sophiris-bio-sphs-earning-somewhat-positive-press-coverage-analysis-finds/1807070.html.

Sophiris Bio Company Profile

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Insider Buying and Selling by Quarter for Sophiris Bio (NASDAQ:SPHS)

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with Analyst Ratings Network's FREE daily email newsletter.